Cost-Effectiveness of Sugemalimab for Metastatic NSCLC in China

A three-state Markov model over 10 years evaluates the cost-effectiveness of sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer in China. The analysis uses 4-year survival data from the GEMSTONE-302 trial and calculates incremental cost-effectiveness ratios against a willingness-to-pay threshold of $40,062.34 per quality-adjusted life year. Zixuan Zhang authored this study, which was last updated on April 25, 2026.

Use Cases

• Compare cost-effectiveness of first-line NSCLC treatments based on ICERs and QALYs mentioned in the description
• Analyze the impact of PD-L1 expression subgroups on treatment economics based on subgroup results
• Assess the influence of drug price and utility values on model outcomes based on sensitivity analysis findings
• Evaluate long-term clinical benefits against cost thresholds for metastatic NSCLC based on the 10-year Markov model

Strengths

• Model is based on 4-year survival data from the GEMSTONE-302 trial
• Analysis includes sensitivity analyses to assess model robustness
• Results are broken down for squamous and non-squamous NSCLC subtypes and PD-L1 expression subgroups

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect geographic bias inherent to a China-based analysis

Provenance

Source

figshare

Collection Method

A three-state Markov model developed using trial data and publicly available sources

Time Range

Model spans 10 years with 21-day cycles

Freshness

Last updated 2026-04-25 05:23:36; freshness should be verified

Geography

China